Cyclophosphamide

Generic Name: Cyclophosphamide

Brand Names: Procytox

Drug Type: Small Molecule

Chemical Formula: C_₇H_₁₅Cl_₂N_₂O_₂P

CAS Number: 50-18-0

Unique Ingredient Identifier: 6UXW23996M

Background: Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.

Indication: Cyclophosphamide is indicated for the treatment of malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast. It is also indicated for the treatment of biopsy-proven minimal change nephrotic syndrome in pediatric patients.

Associated Conditions: Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Acute monocytic leukemia, Adenocarcinoma of the Ovaries, Breast Cancer, Burkitt Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia (CML), Hodgkins Disease (HD), Lung Cancer, Lupus, Lymphocytic Lymphomas, Lymphoma, Multiple Myeloma (MM), Multiple Sclerosis, Nephrotic syndrome with lesion of minimal change glomerulonephritis, Non-Hodgkin's Lymphoma (NHL), Retinoblastoma, Advanced Alibert-Bazin syndrome, Chronic Granulocytic Leukemias, Disseminated Neuroblastoma (NB), Histiocytic lymphoma, Mixed-cell type lymphoma

Associated Therapies: -

Clinical Trials

LAL-Ph-2000: Treatment of Acute Lymphoblastic Leukemia Chromosome Philadelphia Positive

Phase 4

Completed

Conditions: Acute Lymphoblastic Leukemia

First Posted Date: 2007-09-10

Last Posted Date: 2010-01-05

Lead Sponsor: PETHEMA Foundation

Target Recruit Count: 100

Registration Number: NCT00526305

Locations: 🇪🇸
Hospital General de Segovia, Segovia, Spain
🇪🇸
Hospital Universitario de Canarias, Tenerife, Spain
🇪🇸
H.U. Virgen del Rocio, Sevilla, Spain

and more 46 locations

CFAR Study in Patients With Chronic Lymphocytic Leukemia

Phase 2

Completed

Conditions: Chronic Lymphocytic Leukemia
Leukemia

Interventions: Drug: Cyclophosphamide
Drug: Fludarabine
Drug: Alemtuzumab
Drug: Rituximab

First Posted Date: 2007-09-06

Last Posted Date: 2013-03-04

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 60

Registration Number: NCT00525603

Locations: 🇺🇸
The University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States

Non-Myeloablative Allogeneic Stem Cell Transplantation

Not Applicable

Completed

Conditions: Lymphoma

Interventions: Drug: Cyclophosphamide
Drug: Fludarabine
Drug: Rituximab
Procedure: Allogeneic Stem Cell Infusion
Drug: Alemtuzumab

First Posted Date: 2007-09-06

Last Posted Date: 2011-12-07

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 49

Registration Number: NCT00525876

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Study of NY-ESO-1 ISCOMATRIX® in Patients With Measurable Stage III or IV Melanoma

Phase 2

Completed

Conditions: Melanoma

Interventions: Biological: NY-ESO-1 ISCOMATRIX® vaccine
Drug: Cyclophosphamide

First Posted Date: 2007-08-20

Last Posted Date: 2022-10-25

Lead Sponsor: Ludwig Institute for Cancer Research

Target Recruit Count: 46

Registration Number: NCT00518206

Locations: 🇦🇺
Austin Health (Ludwig Institute Oncology Unit), Heidelberg, Victoria, Australia
🇦🇺
Peter MacCallum Cancer Institute, East Melbourne, Victoria, Australia

Doxorubicin or Epirubicin and Cyclophosphamide in Treating Older Women With Invasive Breast Cancer

Phase 3

Conditions: Breast Cancer

First Posted Date: 2007-08-15

Last Posted Date: 2013-08-07

Lead Sponsor: Charing Cross Hospital

Target Recruit Count: 1000

Registration Number: NCT00516425

Locations: 🇬🇧
Southend University Hospital NHS Foundation Trust, Westcliff-On-Sea, England, United Kingdom
🇬🇧
Charing Cross Hospital, London, England, United Kingdom

Vincristine Sulfate, Topotecan Hydrochloride, and Cyclophosphamide With or Without Bevacizumab in Treating Young Patients With Refractory or First Recurrent Extracranial Ewing Sarcoma

Phase 2

Completed

Conditions: Ewing Sarcoma of Bone
Extraosseous Ewing Sarcoma
Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
Peripheral Primitive Neuroectodermal Tumor

Interventions: Drug: topotecan hydrochloride
Drug: vincristine sulfate
Drug: cyclophosphamide
Biological: bevacizumab

First Posted Date: 2007-08-15

Last Posted Date: 2014-09-02

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 7

Registration Number: NCT00516295

Locations: 🇺🇸
Children's Oncology Group, Philadelphia, Pennsylvania, United States

Sunitinib Malate, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide Before Surgery in Treating Patients With Stage IIB-IIIC Breast Cancer

Phase 2

Completed

Conditions: Stage II Breast Cancer
Inflammatory Breast Cancer
Male Breast Cancer
Stage IIIC Breast Cancer
Stage IIIA Breast Cancer
Stage IIIB Breast Cancer

Interventions: Drug: sunitinib malate
Drug: paclitaxel
Drug: doxorubicin hydrochloride
Drug: cyclophosphamide
Biological: filgrastim
Procedure: therapeutic conventional surgery
Other: laboratory biomarker analysis
Other: flow cytometry

First Posted Date: 2007-08-09

Last Posted Date: 2019-08-07

Lead Sponsor: University of Washington

Target Recruit Count: 68

Registration Number: NCT00513695

Locations: 🇺🇸
Skagit Valley Hospital, Mount Vernon, Washington, United States
🇺🇸
Olympic Medical Center, Port Angeles, Washington, United States
🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States

and more 4 locations

Combination Chemotherapy With or Without Bortezomib in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma

Phase 2

Completed

Conditions: Lymphoma

Interventions: Drug: bortezomib
Drug: cyclophosphamide
Drug: doxorubicin hydrochloride
Drug: prednisolone
Drug: vincristine sulfate
Other: questionnaire administration
Procedure: quality-of-life assessment

First Posted Date: 2007-08-09

Last Posted Date: 2014-11-05

Lead Sponsor: University Hospital Plymouth NHS Trust

Target Recruit Count: 50

Registration Number: NCT00513955

Locations: 🇬🇧
Royal Victoria Infirmary, Newcastle-Upon-Tyne, England, United Kingdom
🇬🇧
Birmingham Heartlands Hospital, Birmingham, England, United Kingdom
🇬🇧
Addenbrooke's Hospital, Cambridge, England, United Kingdom

and more 22 locations

Combination Chemotherapy and Denileukin Diftitox in Treating Patients With Newly Diagnosed T-Cell Non-Hodgkin Lymphoma

Not Applicable

Withdrawn

Conditions: Lymphoma

First Posted Date: 2007-08-08

Last Posted Date: 2016-12-15

Lead Sponsor: University of Miami

Registration Number: NCT00513188

Locations: 🇺🇸
University of Miami Sylvester Comprehensive Cancer Center - Miami, Miami, Florida, United States

Rasburicase in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer or Other Disease Undergoing Donor Stem Cell Transplant

Phase 1

Completed

Conditions: Chronic Myeloproliferative Disorders
Graft Versus Host Disease
Leukemia
Lymphoma
Multiple Myeloma and Plasma Cell Neoplasm
Myelodysplastic Syndromes
Myelodysplastic/Myeloproliferative Neoplasms

Interventions: Drug: busulfan
Drug: cyclophosphamide
Drug: cyclosporin-A
Drug: etoposide
Drug: methotrexate
Drug: rasburicase
Drug: sirolimus
Procedure: allogeneic hematopoietic stem cell transplantation
Drug: tacrolimus
Procedure: peripheral blood stem cell transplantation
Radiation: total-body irradiation
Drug: fludarabine
Drug: allopurinol

First Posted Date: 2007-08-08

Last Posted Date: 2017-05-25

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 46

Registration Number: NCT00513474

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy